TABLE 1.
Characteristics of Cancer COVID‐19 Cohort, COVID‐19 Cohort, and Cancer Cohort
| Patients, no. (%) | |||||
|---|---|---|---|---|---|
| Cancer COVID‐19 Cohort (n = 166) | COVID‐19 Cohort (n = 498) | P value a | Cancer Cohort (n = 498) | P value b | |
| Demographics | |||||
| Age, median (IQR), y | 65 (59–70) | 65 (59–70) | 1.000 | 66 (58–73) | .49 |
| Sex | |||||
| Female | 84 (51) | 252 (51) | 1.000 | 252 (51) | 1.000 |
| Male | 82 (49) | 246 (49) | 246 (49) | ||
| Comorbidities | |||||
| Current smoking | 8 (5) | 14 (3) | .211 | 127 (26) | <.001 |
| Hypertension | 55 (33) | 171 (34) | .777 | 135 (27) | .137 |
| Diabetes | 24 (15) | 104 (21) | .069 | 47 (9) | .07 |
| Hyperlipidemia | 33 (20) | 76 (15) | .164 | 34 (7) | <.001 |
| Hyperuricemia | 16 (10) | 42 (8) | .634 | 14 (3) | <.001 |
| Coronary heart disease | 12 (7) | 40 (8) | .739 | 53 (11) | .2 |
| Cerebrovascular disease | 4 (2) | 18 (4) | .453 | 14 (3) | 1.000 |
| COPD | 11 (7) | 25 (5) | .429 | 7 (1) | .001 |
| Chronic kidney disease | 3 (2) | 11 (2) | 1.000 | 7 (1) | 1.000 |
| Chronic liver disease | 5 (3) | 7 (1) | .313 | 28 (6) | .18 |
| Arrhythmia | 8 (5) | 18 (4) | .488 | 27 (5) | .764 |
| Symptoms at admission | |||||
| Fever | 118 (71) | 363 (73) | .652 | NA | NA |
| Chills | 26 (16) | 88 (18) | .552 | NA | NA |
| Headache or dizzy | 26 (16) | 79 (16) | .951 | NA | NA |
| Myalgias | 26 (16) | 104 (21) | .142 | NA | NA |
| Fatigue | 88 (53) | 253 (51) | .622 | NA | NA |
| Rhinorrhea | 10 (6) | 20 (4) | .281 | NA | NA |
| Sore throat | 12 (7) | 69 (14) | .024 | NA | NA |
| Dry cough | 72 (43) | 264 (53) | .031 | NA | NA |
| Expectoration | 60 (36) | 105 (21) | <.001 | NA | NA |
| Hemoptysis | 10 (6) | 7 (1) | .003 | NA | NA |
| Chest congestion | 70 (42) | 203 (41) | .75 | NA | NA |
| Dyspnea | 40 (24) | 79 (16) | .017 | NA | NA |
| Nausea or vomiting | 21 (13) | 45 (9) | .178 | NA | NA |
| Abdominal pain | 8 (5) | 15 (3) | .27 | NA | NA |
| Diarrhea | 31 (19) | 101 (20) | .653 | NA | NA |
| Consciousness disorder | 18 (11) | 20 (4) | .001 | NA | NA |
| Complications | |||||
| Respiratory failure | 27 (16) | 52 (10) | .045 | NA | NA |
| Acute cardiac injury | 3 (2) | 2 (0) | .195 | NA | NA |
| Acute kidney injury | 29 (18) | 41 (8) | .001 | NA | NA |
| Acute liver injury | 53 (32) | 110 (22) | .011 | NA | NA |
| Prothrombotic coagulopathy | 2 (1) | 4 (1) | 1.000 | NA | NA |
| Electrolytic disturbance | 28 (17) | 63 (13) | .171 | NA | NA |
| In‐hospital infection | 6 (4) | 16 (3) | .802 | NA | NA |
| Treatment | |||||
| Antiviral drug | 108 (65) | 359 (72) | .086 | NA | NA |
| Intravenous antibiotics | 88 (53) | 224 (45) | .073 | NA | NA |
| Intravenous antifungal | 20 (12) | 36 (7) | .053 | NA | NA |
| Anticoagulation | 50 (30) | 37 (7) | <.001 | NA | NA |
| Intravenous corticosteroids | 44 (27) | 70 (14) | <.001 | NA | NA |
a
Cancer COVID‐19 Cohort vs COVID‐19 Cohort.
b
Cancer COVID‐19 Cohort vs Cancer Cohort.